Tishman Speyer got the nod to lead the development of the first phase of Harvard’s new Enterprise Research Campus in Allston, which will be landing in the middle of one of the busiest biotech hubs in the world — where demand for new space is sky-high. And they’ll be supported
Roche has already budgeted for future commercial manufacturing builds and established a network of contract manufacturers as it preps for the launch of its GLP-1/GIP…
Roche’s once-daily oral weight loss pill helped Phase 1 subjects lose up to 7.3% of their body weight within one month, which is less than…
GSK is ending further development of its therapeutic vaccine for herpes after the candidate failed to prevent recurrent symptom flare ups in infected adults in…
A drug developer aiming to create more potent, effective antibodies unveiled a $35 million Series A on Wednesday with the support of the Bill &…
GSK is closing down a facility and is winding down antibiotic manufacturing operations at another factory as Novartis’ Sandoz chooses to end its four-year contract.…
Bain Capital Life Sciences has reeled in about $3 billion for its fourth fund, Endpoints News has learned. The Boston-based firm has been on a…
An FDA advisory committee raised concerns Monday about whether Iterum’s application for a new oral antibacterial to treat urinary tract infections is restrictive enough to…
A few months after Summit Therapeutics shocked the oncology world with an early claim that its lung cancer drug ivonescimab had beaten Merck’s Keytruda, it…
The FDA has raised concerns about potential
CAR T cell therapy startup Arsenal Biosciences has reeled in a $325 million Series C as it works through two early-stage trials in solid tumors.…
